Clinical applications of newer radionuclide therapies
- 1 May 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (8), 994-1003
- https://doi.org/10.1016/j.ejca.2005.12.020
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Feasibility of Dosimetry-Based High-Dose 131I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic NeuroblastomaCancer Biotherapy & Radiopharmaceuticals, 2005
- Tumor response and toxicity with multiple infusions of high dose 131I‐MIBG for refractory neuroblastomaPediatric Blood & Cancer, 2004
- Hematologic Toxicity of High-Dose Iodine-131–Metaiodobenzylguanidine Therapy for Advanced NeuroblastomaJournal of Clinical Oncology, 2004
- High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytomaCancer, 2003
- Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceSeminars in Nuclear Medicine, 2002
- Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastomaBone Marrow Transplantation, 2001
- Nuclear medicine imaging of neuroendocrine tumoursAnnals of Oncology, 2001
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.Journal of Clinical Oncology, 1992